A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

NCT05172856 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: IBI321

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.